~17 spots leftby Apr 2026

Transcranial Magnetic Stimulation for Mild Cognitive Impairment

(TAMCI Trial)

Recruiting in Palo Alto (17 mi)
Overseen byPrasad R. Padala, MBBS MBBS
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: VA Office of Research and Development
No Placebo Group
Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

Apathy, a profound loss of initiative and motivation, is often seen in older Veterans with memory problems. Apathy leads to serious health problems, increases dependency, and caregiver burden. If untreated, apathy hastens the progression to frank dementia. In a pilot study, the investigators found that apathy, working memory, and function can be restored using magnetic stimulation in some but not all older Veterans. The reason for this variation is unknown. The investigators propose a three-phase study in 125 older Veterans with mild memory problems. Their motivation, memory, and function will be measured periodically. Veterans with apathy that are eligible for treatment will receive either real or sham magnetic stimulation to the front part of their brain over 20 sessions. Genetic testing and biomarkers will be used to differentiate those who respond to magnetic stimulation from those who do not. Impact on function, quality of life, and rates of progression to dementia will also be studied. A project modification was obtained to conduct a cross-sectional study, the COVID Dementia study. The cross-sectional study will examine the effect of the pandemic on MCI and AD patients and their caregivers ("individual COVID-related factors" such as, personally infected, death of a friend/family member, economic hardship, disruption in care, isolation), barriers to telehealth, caregiver distress, NPS, cognition (including onset of delirium), and function. Our goal is to develop a multi-pronged, remotely deliverable intervention to address consequences of healthcare disruptions in older Veterans with cognitive impairment. Aim 1. To explore the association between COVID-related factors and neuropsychiatric symptoms in individuals with MCI and AD. Hypothesis: The number of COVID-related factors endorsed by caregivers will be positively correlated with the severity of NPI-Q in individuals with MCI and AD. Aim 2. To assess cognition (telephonic version of the Montreal Cognitive Assessment; tMoCA12, and daily function (Functional Activities Questionnaire; FAQ13). Hypothesis: The number of COVID-related factors will be positively correlated with the severity of cognitive and functional deficits in individuals with MCI and AD. Aim 3. To explore the associations among COVID-related factors and caregiver distress. Hypothesis: Caregiver resilience and perceived social support will modify the association between COVID-related factors and severity of distress in caregivers.

Eligibility Criteria

This trial is for older Veterans with mild memory problems who show signs of apathy. They must meet specific criteria for Mild Cognitive Impairment, have a caregiver, score at least 23 on the MMSE (a test of mental function), and if taking antidepressants, be on a stable dose for one month.

Inclusion Criteria

I have been on the same dose of antidepressants for at least a month.
You don't have someone who can take care of you during the study.
You have a score lower than 23 on the MMSE (Mini-Mental State Examination) test.
See 2 more

Treatment Details

Interventions

  • Transcranial Magnetic Stimulation (Behavioural Intervention)
Trial OverviewThe study tests whether Transcranial Magnetic Stimulation (TMS) can improve motivation, memory, and functioning in participants. It involves real or sham TMS over 20 sessions targeting the brain's frontal area. The study also examines genetic factors that may influence response to treatment.
Participant Groups
3Treatment groups
Active Control
Placebo Group
Group I: Apathy +, rTMS -Active Control1 Intervention
This arm will be followed without intervention
Group II: rTMSActive Control1 Intervention
This group will be randomized to receive rTMS treatment
Group III: ShamPlacebo Group1 Intervention
This group will be randomized to receive sham treatment

Transcranial Magnetic Stimulation is already approved in United States, Canada, European Union for the following indications:

πŸ‡ΊπŸ‡Έ Approved in United States as Transcranial Magnetic Stimulation for:
  • Major Depressive Disorder
  • Obsessive Compulsive Disorder
πŸ‡¨πŸ‡¦ Approved in Canada as Transcranial Magnetic Stimulation for:
  • Major Depressive Disorder
πŸ‡ͺπŸ‡Ί Approved in European Union as Transcranial Magnetic Stimulation for:
  • Major Depressive Disorder

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, ARNorth Little Rock, AR
Loading ...

Who Is Running the Clinical Trial?

VA Office of Research and DevelopmentLead Sponsor
University of ArkansasCollaborator
Central Arkansas Veterans Healthcare SystemCollaborator

References